Publication:

Sorafenib induced pustular psoriasis in a patient of hepatocellular carcinoma: a rare case report

Pustular psoriasis is the least common form of psoriasis characterized by the formation of psoriatic plaques studded with pustules. Sorafenib is an oral multi-targeted kinase inhibitor approved for the management of hepatocellular carcinoma. We report a biopsy proven case of pustular psoriasis induced by Sorafenib in a patient of hepatocelluar carcinoma. Cutaneous adverse effects with Sorafenib are rare but are not life threatening. We are reporting this case because of the rarity of association and for highlighting the need for early detection and management.